NASDAQ · Biotechnology

Cytokinetics, Incorporated (CYTK) Stock

$62.79 +1.26% NASDAQ: CYTK Healthcare

Valuation

MetricValue
Price$62.79
Market Cap$7.81B
P/E Ratio-8.48
P/B Ratio-46.53
P/S Ratio107.18
EPS (TTM)$0.00
52-Week High$88.31
52-Week Low$54.30
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE163.98%
ROA-46.45%
ROCE-40.42%
Gross Margin-695.45%
Operating Margin-695.45%
Net Margin-784.02%
Debt/Equity-7.32
Current Ratio4.54

Annual Financials (USD)

Metric20212022202320242025
Revenue$70.0M$95.0M$8.0M$18.0M$88.0M
Operating Profit$-186.0M$-324.0M$-496.0M$-536.0M$-612.0M
Net Profit$-215.0M$-389.0M$-526.0M$-590.0M$-785.0M
EPS$-2.80$-4.33$-5.45$-5.26$-6.54
Op Margin-264.5%-342.8%-6589.7%-2902.7%-695.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$841.0M$1.0B$824.0M$1.4B$1.4B
Total Liabilities$597.0M$1.1B$1.2B$1.5B$2.1B
Cash$113.0M$66.0M$113.0M$95.0M$123.0M
Borrowings$270.0M$750.0M$756.0M$789.0M$1.3B

Latest News

All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy Zacks · Jul 15, 2026 Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet Zacks · Jul 15, 2026 CYTK: Lowering target price to $86.00 Argus Research · Jul 15, 2026 What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% Motley Fool · Jul 14, 2026 Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing MT Newswires · Jul 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-143.0M$-300.0M$-414.0M$-396.0M$-510.0M
Investing Cash Flow$-197.0M$-273.0M$238.0M$-557.0M$-8.0M
Financing Cash Flow$8.0M$164.0M$58.0M$233.0M$-2.0M
Net Cash Flow$30.0M$-45.0M$46.0M$-18.0M$30.0M
Free Cash Flow$-191.0M$-311.0M$-416.0M$-400.0M$-535.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.25
EV / EBITDA-10.53
FCF Yield-7.64%
Quick Ratio6.66
Interest Coverage-5.64
Return 1Y1.17%
Return 3Y100.49%
Return 5Y57.92%

Ownership

Insiders Held0.67%
Institutions Held118.82%
Institutions Float Held119.62%
Institutional HolderSharesReport Date
T. Rowe Price Investment Management, Inc.17,523,8402026-03-31
Blackrock Inc.16,548,0112026-03-31
FMR, LLC10,723,1402026-03-31
Wellington Management Group, LLP8,009,4892026-03-31
Vanguard Portfolio Management LLC5,843,7822026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCDABioCardia, Inc. $1.07 +0.94% -1.54 $15.93M 0.00%
BRVEBraveheart Bio, Inc. $20.01 +4.79% -21.64 $1.41B 0.00%
KARDKardigan, Inc. $15.42 +8.61% -6.64 $1.38B 0.00%
RNAAtrium Therapeutics, Inc. $8.39 +1.57% -2.15 $143.52M 0.00%
TNYATenaya Therapeutics, Inc. $0.55 +1.71% -1.06 $120.11M 0.00%

About Cytokinetics, Incorporated

Cytokinetics, Incorporated is led by CEO Robert I. Blum, employs 673 people, headquartered in South San Francisco, US, publicly traded since 2004.

Cytokinetics, Incorporated (CYTK) stock trades at $62.79 with a market capitalization of $7.81B. The stock is valued at a price-to-earnings (P/E) ratio of -8.48, price-to-book of -46.53, price-to-sales of 107.18. Over the past 52 weeks the stock has ranged between $54.30 and $88.31, and currently trades 28.9% below its 52-week high.

On profitability, Cytokinetics, Incorporated generates a return on equity (ROE) of 163.98% — well above the market average, a sign of a high-quality business, return on capital employed of -40.42%, an operating margin of -695.45%, a net profit margin of -784.02%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1176.50 +0.59% JNJ Johnson & Johnson $260.45 +1.55% ABBV AbbVie Inc. $276.42 +1.47% MRK Merck & Company, Inc. Common Stock (new) $146.15 +2.64% UNH UnitedHealth Group Incorporated Common Stock (DE) $380.92 +2.69% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $660.31 +1.28% AMGN Amgen Inc. $417.07 +2.36% GILD Gilead Sciences, Inc. $150.86 +2.56% ABT Abbott Laboratories $99.23 +0.75% NVO Novo Nordisk A/S $38.42 +0.62%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides